Nigel Rawson is a pharmacoepidemiologist, pharmaceutical policy researcher, and President of Eastlake Research Group in Oakville, Ontario. He has also been a Sessional Faculty member in the DeGroote School of Business at McMaster University. Educated in the United Kingdom, he holds an MSc in statistics from the University of Newcastle-upon-Tyne and a PhD in pharmacoepidemiology from the University of Southampton. Dr. Rawson has performed epidemiologic studies of the use of drugs and their outcomes for over 30 years and published more than 100 book chapters and articles in peer-reviewed journals. He held academic research positions in the Universities of London and Southampton in the United Kingdom until the end of 1989, when he became a research scientist at the University of Saskatchewan and later Merck Frosst/MRC Research Professor in Pharmacoepidemiology. He was subsequently Professor of Pharmacoepidemiology at Memorial University of Newfoundland. His research activities focused on population-based studies of the use and safety of drugs using administrative healthcare utilization data and the evaluation of issues impacting access to new drugs. Dr. Rawson has also been a senior researcher in the Center for Health Care Policy and Evaluation, an independent research team in United Health Group (one of the largest health insurers in the United States), where he collaborated with the Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada providing advice and analysis for the company’s current and developing medicines and vaccines. Dr. Rawson established Eastlake Research Group in 2012 with a mission to create data-driven responses to pharmaceutical and health policy issues.